Moody Aldrich Partners LLC boosted its position in shares of CONMED Co. (NASDAQ:CNMD) by 17.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,799 shares of the medical technology company’s stock after purchasing an additional 4,079 shares during the period. Moody Aldrich Partners LLC owned approximately 0.10% of CONMED worth $2,001,000 at the end of the most recent quarter.
Other hedge funds have also recently modified their holdings of the company. CWM Advisors LLC purchased a new position in CONMED during the first quarter worth about $28,000. FinTrust Capital Advisors LLC purchased a new stake in CONMED in the 1st quarter valued at approximately $44,000. Tower Research Capital LLC TRC purchased a new stake in CONMED in the 1st quarter valued at approximately $60,000. Exchange Traded Concepts LLC boosted its holdings in CONMED by 105.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,060 shares of the medical technology company’s stock valued at $61,000 after purchasing an additional 544 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. purchased a new stake in CONMED in the 1st quarter valued at approximately $150,000.
In other news, EVP Wilfredo Ruiz-Caban sold 9,919 shares of the stock in a transaction on Friday, June 5th. The stock was sold at an average price of $82.02, for a total value of $813,556.38. Following the transaction, the executive vice president now owns 25,592 shares of the company’s stock, valued at approximately $2,099,055.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 4.38% of the company’s stock.
Shares of NASDAQ:CNMD traded down $4.80 during midday trading on Friday, hitting $82.54. The company’s stock had a trading volume of 417,893 shares, compared to its average volume of 417,622. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.40 and a current ratio of 2.48. The stock’s 50 day simple moving average is $74.62 and its 200 day simple moving average is $79.48. The stock has a market capitalization of $2.35 billion, a price-to-earnings ratio of 86.88, a PEG ratio of 2.18 and a beta of 0.56. CONMED Co. has a fifty-two week low of $37.66 and a fifty-two week high of $116.81.
CONMED (NASDAQ:CNMD) last issued its earnings results on Wednesday, July 29th. The medical technology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.95) by $0.88. The business had revenue of $157.80 million for the quarter, compared to analyst estimates of $126.59 million. CONMED had a net margin of 3.00% and a return on equity of 11.18%. The firm’s revenue was down 33.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.56 EPS. As a group, analysts anticipate that CONMED Co. will post 3.1 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, July 6th. Investors of record on Monday, June 15th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.97%. The ex-dividend date was Friday, June 12th. CONMED’s dividend payout ratio (DPR) is presently 30.30%.
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.
Read More: What is the return on assets (ROA) ratio?
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.